Investment Summary

Vivo Capital Invests In Seran

On January 5, 2021, growth capital firm Vivo Capital invested in life science company Seran

Investment Highlights
  • This is Vivo Capital’s 12th transaction in the Life Science sector.
  • This is Vivo Capital’s 15th transaction in the United States.
  • This is Vivo Capital’s 1st transaction in Oregon.

Investment Summary
Date 2021-01-05
Target Seran
Sector Life Science
Investor(s) Vivo Capital
Deal Type Growth Capital

Target

Seran

Bend, Oregon, United States
Seran is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. Seran was founded in 2016 and is based in Bend, Oregon.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Vivo Capital

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1996
PE ASSETS 6.4B USD
Size Mega
Type Sector Focused
DESCRIPTION

Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.

DEAL STATS #
Overall 17 of 18
Sector (Life Science) 12 of 13
Type (Growth Capital) 1 of 1
State (Oregon) 1 of 1
Country (United States) 15 of 15
Year (2021) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-19 Harmony

Plymouth Meeting, Pennsylvania, United States

Harmony is a biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders. Harmony was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-13 IO Biotech

Copenhagen, Denmark

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech's pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech was founded in 2014 and is based in Copenhagen, Denmark.

Buy -
Mergr

Product

Company

Legal